New data sharpen the apomorphine vs ropinirole debate

A new head-to-head evidence base is reframing a familiar ER question: when a dog needs emesis, should the team reach for apomorphine or ropinirole? The debate has intensified as ropinirole, sold as Clevor, has moved from novel FDA-approved option to a real-world competitor to apomorphine. While earlier studies positioned ropinirole as broadly comparable, newer emergency-setting data suggest the tradeoffs may be more meaningful than many clinics first assumed. (fda.gov)

The background matters here. Apomorphine has long been a mainstay for inducing emesis in dogs, but in the U.S. it is used extra-label for that purpose. Ropinirole changed the landscape when the FDA approved Clevor on June 16, 2020, as the first approved product specifically indicated to induce vomiting in dogs. That gave clinicians an on-label option delivered as eye drops rather than an injectable or compounded product, a distinction that appealed to practices thinking about staff safety, handling, and workflow. (fda.gov)

Initial evidence helped drive that enthusiasm. In the FDA-supported field study, 95% of dogs treated with ropinirole vomited within 30 minutes. A 2023 JAVMA clinical trial in 279 client-owned dogs with suspected toxin or foreign material ingestion found 91.4% vomited after ropinirole administration, with an average time to emesis of 11 minutes; the authors concluded ropinirole was less effective than apomorphine for inducing vomiting, but similarly effective at evacuating all ingested material. Meanwhile, a 2025 crossover study in 24 healthy dogs found no difference in overall efficacy between the two drugs, although apomorphine acted faster and ropinirole was associated with more vomiting episodes and more early antiemetic use. (fda.gov)

The newest wrinkle comes from a 2025 study in the Journal of Veterinary Emergency and Critical Care, which compared ropinirole and IV apomorphine in an emergency setting. According to VetGirl’s summary of the trial, this was a prospective randomized clinical study run from October 2021 through March 2023 at two specialty referral hospitals and included 132 client-owned dogs after suspected or confirmed toxin or foreign-body ingestion. Dogs were randomized to ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs), with a second identical dose given if vomiting had not occurred within 20 minutes and monitoring continuing for 40 minutes total. The study excluded dogs under 4.5 months of age, under 1.8 kg, those with ocular disease, CNS or hepatic disease, contraindications to emesis such as caustic or volatile ingestions, or prior antiemetic treatment. In that real-world population, ropinirole had a lower first-dose emetic success rate, a longer median time to first emetic event, more minor adverse events, and more protracted vomiting requiring rescue therapy. That finding is important because it reflects the messier reality of emergency patients, not just healthy research dogs or historical comparisons. In other words, the answer may depend less on theoretical efficacy and more on what teams need in a time-sensitive toxicology case. (pubmed.ncbi.nlm.nih.gov)

Industry and academic commentary has been pointing to this tension for a while. The University of Illinois College of Veterinary Medicine noted that ropinirole’s advantages include FDA approval and ophthalmic administration, while apomorphine typically produces emesis faster, especially IV, and remains more familiar in urgent care settings. The same review also flagged apomorphine’s hazardous-drug handling issues and the possibility of more serious CNS and respiratory effects, underscoring that the choice isn’t simply about speed or label status alone. VetGirl’s rundown of the 2025 trial adds another practical layer: emergency clinicians were not just comparing whether dogs vomited, but how quickly, how many emetic events occurred, and how often rescue antiemetics were needed afterward. (vetmed.illinois.edu)

Why it matters: For veterinary teams, this is a practical protocol issue. In a dog with a narrow decontamination window, faster onset and stronger first-dose performance may outweigh the convenience of an ophthalmic product. In a general practice setting, however, an FDA-approved, ready-to-use emetic may still be attractive, particularly where apomorphine compounding, hazardous handling, or staff familiarity create friction. The larger takeaway is that emetic selection may need to become more case-dependent: patient age and size, time since ingestion, aspiration risk, clinic workflow, and the need for rapid reversal all matter. The newer emergency data also reinforce the importance of having a clear rescue plan when vomiting is prolonged. (vetmed.illinois.edu)

There’s also a communication angle with pet parents. Because ropinirole is an eye drop, it may appear gentler or simpler, but veterinary supervision is still essential. FDA says Clevor should be administered only by veterinary personnel, because clinicians must assess contraindications and monitor for adverse reactions. That’s a useful reminder as more pet parents encounter online discussions about home decontamination or older advice around peroxide. (fda.gov)

One adjacent development may also matter for clinic workflow: Dechra has announced FDA approval of Emeprev, an injectable maropitant product positioned as the first FDA-approved bioequivalent to the most widely used antiemetic in companion animals. According to the company announcement, the product does not require refrigeration and includes benzyl alcohol, which reduced injection discomfort in dogs in healthy-laboratory studies. For practices thinking through emesis protocols, that does not change the emetic choice itself, but it could make post-emesis antiemetic management a little easier from a storage and patient-comfort standpoint when rescue therapy is needed. The product is expected to be available through major veterinary distributors in early 2026.

What to watch: The next phase will likely center on whether emergency and toxicology services revise first-line emesis protocols, and whether additional comparative studies in real-world patients help define which dogs are best suited for ropinirole, which still favor apomorphine, and when rescue antiemetics should be built into the plan. Availability of newer injectable maropitant options may also shape how clinics operationalize those rescue protocols. (pubmed.ncbi.nlm.nih.gov)